openPR Logo
Press release

Eigen Bio's AI Outperforms DeepMind's AlphaFold3, Secures Top 3 Global Rank in Stanford RNA 3D Structure Prediction Challenge

09-29-2025 10:08 PM CET | Health & Medicine

Press release from: Getnews

/ PR Agency: NewswireJet
Eigen Bio's AI Outperforms DeepMind's AlphaFold3, Secures Top 3

Image: https://www.globalnewslines.com/uploads/2025/09/1759156068.jpg

NEW YORK - September 29, 2025 - Eigen Bio, announced that it was awarded the #3 overall ranking worldwide in the Stanford University RNA 3D Structure Prediction Challenge. In a landmark result, Eigen Bio's proprietary AI model placed ahead of Google DeepMind's AlphaFold3, definitively positioning Eigen Bio at the forefront of computational structural biology.

Image: https://www.globalnewslines.com/uploads/2025/09/13aa472b90bffc04dc09c11ba1871ecf.jpg

The competition was one of the largest scientific challenges of its kind, attracting a massive global talent pool: 10,376 registrations from 89 countries, culminating in 18,386 submissions from 1,485 active teams. Eigen Bio's exceptional performance places it in the top 0.2% of participants, a testament to the power and sophistication of its foundational AI platform.

A New Frontier in Biology

This achievement is a pivotal moment in biological science. Just as AlphaFold2's solution to the protein folding problem heralded a new era in biology and contributed to a Nobel Prize, the accurate prediction of RNA structure is widely considered the next great challenge in molecular biology. RNA molecules are fundamental to life, acting as messengers, enzymes, and regulators of cellular processes. However, their complex and dynamic 3D shapes have remained notoriously difficult to predict.

"To outperform a titan like DeepMind in what is arguably the next frontier after protein folding is a watershed moment," said Sang Lee, founder and CEO of Eigen Bio. "It's not just a competition win; it's validation of our unique approach to AI and a powerful demonstration that our platform can solve fundamental biological problems previously thought to be intractable. We are building the foundational model that will decode the language of RNA and ultimately biological function."

Accelerating the Future of Medicine

The ability to accurately and rapidly predict RNA 3D structures is a paradigm shift for medicine. It unlocks the potential to:

* Design Novel Therapeutics: Create highly specific RNA-based drugs, such as mRNA vaccines, siRNAs, and aptamers, to target diseases like cancer, viral infections, and genetic disorders with unprecedented precision.
* Accelerate Drug Discovery: Dramatically shorten the timeline and reduce the cost of developing new medicines by modeling drug-RNA interactions in silico.
* Uncover Disease Mechanisms: Provide researchers with an essential tool to understand how dysfunctional RNA contributes to disease, paving the way for new diagnostic and therapeutic strategies.

Eigen Bio's success in this challenge is testament that its core technology is not just theoretical but a world-class, validated solution poised to drive the future of biotechnology.

A Foundation for Growth and Innovation

This milestone provides significant momentum for Eigen Bio's mission to engineer biology and redefine medicine. Eigen Bio is leveraging its validated AI platform to build a vertically integrated pipeline spanning RNA-based diagnostics, AI-powered drug discovery, and novel therapeutic development.

"This result is a clear signal to the industry, our partners, and the investment community," Sang Lee continued. "We have a foundational technology that is world class, and we are moving with urgency and focus to translate this computational power into life-saving products. We invite collaborators and investors who share our vision to join us in building the next chapter of medicine."

About Eigen Bio

Eigen Bio is a next-generation biotechnology company pioneering the use of artificial intelligence to unlock the biology of RNA. By combining advanced machine learning with deep molecular expertise, Eigen Bio is building the world's most powerful RNA-focused AI engine - enabling breakthroughs in diagnostics, drug discovery, and therapeutic development.

Contact

Dairo Isomura, Eigen Bio, dairo.isomura@eigenbioai.com
Media Contact
Company Name: Eigen Bio
Contact Person: Dairo Isomura
Email: Send Email [http://www.universalpressrelease.com/?pr=eigen-bios-ai-outperforms-deepminds-alphafold3-secures-top-3-global-rank-in-stanford-rna-3d-structure-prediction-challenge]
Country: United States
Website: http://www.eigenbioai.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Eigen Bio's AI Outperforms DeepMind's AlphaFold3, Secures Top 3 Global Rank in Stanford RNA 3D Structure Prediction Challenge here

News-ID: 4202838 • Views:

More Releases from Getnews

The U.S. Green Card: Turning a Temporary Stay into a Permanent American Future
The U.S. Green Card: Turning a Temporary Stay into a Permanent American Future
Image: https://www.globalnewslines.com/uploads/2025/12/1766183100.jpg For many people, a U.S. visa is only the beginning. What they truly want is certainty - the ability to live, work, and plan their future in the United States without expiry dates, renewals, or ongoing fear that a single decision could unravel years of effort. That certainty is called a Green Card. Yet despite its importance, the Green Card [https://larhdellaw.com/] process is often misunderstood. Some believe it is only for
The L-1 Visa: How Global Businesses Expand to the U.S. Without Starting From Scratch
The L-1 Visa: How Global Businesses Expand to the U.S. Without Starting From Scr …
Image: https://www.globalnewslines.com/uploads/2025/12/1766182907.jpg For international companies with ambitions to enter the United States, few visa options are as powerful - or as misunderstood - as the L-1 Intracompany Transfer Visa. When used correctly, the L-1 visa allows established businesses to expand into the U.S. market, transfer trusted senior staff, and build a long-term American presence without relying on lotteries, third-party sponsors, or speculative investment routes. When used incorrectly, it becomes one of the
The B-1/B-2 Visitor Visa: Why Careful Preparation Matters More Than Ever
The B-1/B-2 Visitor Visa: Why Careful Preparation Matters More Than Ever
Image: https://www.globalnewslines.com/uploads/2025/12/1766182346.jpg The B-1/B-2 visitor visa [https://larhdellaw.com/]is often described as the most common U.S. visa. That description, while true, can be misleading. Its familiarity causes many applicants to underestimate how closely these visas are scrutinised - and how easily an application can be refused. In today's immigration environment, visitor visas are assessed with a level of caution that surprises even experienced international travellers. The rules themselves have not dramatically changed, but how
The E-2 Visa Explained: How to Invest in the U.S. Without Buying a Green Card (and Why Many Applications Fail)
The E-2 Visa Explained: How to Invest in the U.S. Without Buying a Green Card (a …
Image: https://www.globalnewslines.com/uploads/2025/12/1766182716.jpg For entrepreneurs, investors, and business owners looking to live and work in the United States, the E-2 Treaty Investor Visa remains one of the most attractive - and misunderstood - visa options available. Every year, we speak with applicants who have invested significant money, launched businesses, or even hired staff, only to discover that their E-2 application was refused or delayed due to avoidable legal and strategic errors. The truth

All 5 Releases


More Releases for Bio

Human Plasma Products Market 2023: Industry Future Trends | Takeda, CSL, Grifols …
The Human Plasma Products market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with
Gene Therapy Products Market | Advantagene, Avalanche Bio, Bluebird Bio, Cellado …
The global gene therapy products market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the gene therapy products market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
Bio-based Polymethyl Methacrylate (Bio-PMMA) Market 2023 | Detailed Report
The Bio-based Polymethyl Methacrylate (Bio-PMMA) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Bio-based Polymethyl Methacrylate (Bio-PMMA) research report
Bio Pharma Buffer Market – A comprehensive study by Key Players: Bio-Rad, Lonz …
Latest Market intelligence report released by HTF MI with title "COVID-19 Outbreak-Global Bio Pharma Buffer Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020" is designed covering micro level of analysis by manufacturers and key business segments. The COVID-19 Outbreak-Global Bio Pharma Buffer Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary
IVIG Market Anticipated a Noteworthy CAGR during 2019-2024 & Companies Included …
A report added to the rich database of Qurate Business Intelligence, titled “World IVIG Market by Product Type, Players and Regions - Forecast to 2024”, provides a 360-degree overview of the Global market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the
Green & Bio-based Solvents Market Analysis, Demand, & Opportunities till 2023 | …
A latest research report titled as “Green & Bio-based Solvents Market for Paints & Coatings, Printing Inks, Commercial & Domestic Cleaning, Adhesives & Sealants, Pharmaceutical, Cosmetics, and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023” has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the